The authors conclude that development of rash should be considered an indicator of a positive clinical outcome in erlotinib-treated patients.

Major toxicities induced by erlotinib treatment are diarrhea and acne-like skin rash. No survival advantage has been seen with the addition of erlotinib to platinum-based combination chemotherapy ...